Abstract
Overexpression of the HER2 (neu/c-erbB-2) oncogene frequently coincides with an aggressive clinical course of certain human adenocarcinomas. Expression and secretion of aberrant HER2 splice variants has been reported in various cell lines and tissues and can interfere with the oncogenic HER2 activity. Here we demonstrate, using two different approaches, that expression of a truncated 100 kDa HER2 variant which encodes the extracellular domain of HER2 (HER-ECD) inhibits growth factor-mediated tumour cell proliferation. A HER2-ECD cDNA encoding the truncated variant was overexpressed in MCF7 breast cancer cells. HER2-ECD overexpression decreased spontaneous proliferation of MCF7 cells as well as heregulin-mediated soft agar colony formation. Concomitantly, heregulin-induced phosphorylation of HER4 as well as downstream activation of p44/p42 MAP-kinases was decreased. To confirm these data, ribozymes were targeted to the 3′-untranslated region of the 2.3 kb HER2-ECD mRNA which is spontaneously expressed in MKN7 gastric cancer cells. HER2-ECD-targeted ribozymes downregulated HER2-ECD expression and enhanced EGF-mediated soft agar colony formation of MKN7 cells. In parallel, EGF-induced activation of p44/p42 MAP-kinases and activation of c-Fos expression were increased in ribozyme-transfected MKN7 cells. Finally, in RT–PCR we found a trend towards a progressive loss of 2.3 kb HER2-ECD mRNA expression in more advanced gastric tumours. These data show that the HER2-ECD variant inhibits growth factor-mediated tumour cell proliferation suggesting an important role during the progression of human cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aigner A, Malerczyk C, Houghtling R, Wellstein A . 2000 Growth Factors 18: 51–62
Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM . 2000 J. Clin. Oncol. 18: 2201–2209
Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A, Massuti B, Cortes-Funes H, Lloveras B . 2000 Clin. Cancer Res. 6: 2356–2362
Czubayko F, Riegel AT, Wellstein A . 1994 J. Biol. Chem. 269: 21358–21363
Doherty JK, Bond C, Jardim A, Adelman JP, Clinton GM . 1999 Proc. Natl. Acad. Sci. USA 96: 10869–10874
Flickinger TW, Maihle NJ, Kung HJ . 1992 Mol. Cell. Biol. 12: 883–893
Gebhardt F, Zanker KS, Brandt B . 1998 Biochem. Biophys. Res. Comm. 247: 2 319–323
Graus-Porta D, Beerli RR, Daly JM, Hynes NE . 1997 EMBO J. 16: 1647–1655
Graus-Porta D, Beerli RR, Hynes NE . 1995 Mol. Cell. Biol. 15: 1182–1191
Hsieh SS, Malerczyk C, Aigner A, Czubayko F . 2000 Int. J. Cancer 86: 644–651
Juhl H, Downing SG, Wellstein A, Czubayko F . 1997 J. Biol. Chem. 272: 29482–29486
Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y . 1996 EMBO J. 15: 254–264
Kendall RL, Thomas KA . 1993 Proc. Natl. Acad. Sci. USA 90: 10705–10709
Lee H, Maihle NJ . 1998 Oncogene 16: 3243–3252
Lewis GD, Lofgren JA, McMurtrey AE, Nuijens A, Fendly BM, Bauer KD, Sliwkowski MX . 1996 Cancer Res. 56: 1457–1465
Mosley B, Beckmann MP, March CJ, Idzerda RL, Gimpel SD, VandenBos T, Friend D, Alpert A, Anderson D, Jackson J . 1989 Cell 59: 335–348
Petch LA, Harris J, Raymond VW, Blasband A, Lee DC, Earp HS . 1990 Mol. Cell. Biol. 10: 2973–2982
Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y . 1996 EMBO J. 15: 2452–2467
Reiter JL, Maihle NJ . 1996 Nucleic Acids Res. 24: 4050–4056
Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL . 1985 J. Immunol. 135: 3172–3177
Salomon DS, Brandt R, Ciardiello F, Normanno N . 1995 Critical Reviews in Oncology and Hematology 19: 183–232
Schulte AM, Lai S, Kurtz A, Czubayko F, Riegel AT, Wellstein A . 1996 Proc. Natl. Acad. Sci. USA 93: 14759–14764
Scott GK, Robles R, Park JW, Montgomery PA, Daniel J, Holmes WE, Lee J, Keller GA, Li WL, Fendly BM . 1993 Mol. Cell. Biol. 13: 2247–2257
Slamon DJ, Clark GM, Wong SG, Levin W, Ullrich A, McGuire RL . 1987 Science 235: 177–182
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A . 1989 Science 244: 707–712
Souttou B, Ahmad S, Riegel AT, Wellstein A . 1997 J. Biol. Chem. 272: 19588–19593
Tavernier J, Tuypens T, Plaetinck G, Verhee A, Fiers W, Devos R . 1992 Proc. Natl. Acad. Sci. USA 89: 7041–7045
Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y . 1996 Mol. Cell. Biol. 16: 5276–5287
Tzahar E, Yarden Y . 1998 Biochim. Biophys. Acta 1377: M25–M37
Zabrecky JR, Lam T, McKenzie SJ, Carney W . 1991 J. Biol. Chem. 266: 1716–1720
Acknowledgements
We thank Dr A Wellstein (Lombardi Cancer Center, Washington DC) for insightful discussions and helpful suggestions. We gratefully acknowledge the support provided by the US Army Medical Research Materiel Command Breast Cancer Program (DAMD 17-96-I-6030; to F Czubayko), by the Deutsche Forschungsgemeinschaft (DFG, Germany Ju 389/1-1; to H Juhl and F Czubayko) and by the Lombardi Cancer Center Flow Cytometry / Cell sorting shared resource (supported by the US Public Health Service grant; 2P30-CA-51008).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Aigner, A., Juhl, H., Malerczyk, C. et al. Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation. Oncogene 20, 2101–2111 (2001). https://doi.org/10.1038/sj.onc.1204305
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204305
Keywords
This article is cited by
-
HER2-PI9 and HER2-I12: two novel and functionally active splice variants of the oncogene HER2 in breast cancer
Journal of Cancer Research and Clinical Oncology (2021)
-
The HER2 Signaling Network in Breast Cancer—Like a Spider in its Web
Journal of Mammary Gland Biology and Neoplasia (2014)
-
TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line
Tumor Biology (2013)
-
RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo
Gene Therapy (2005)